Cost-effectiveness analysis reveals benefits of continuous glucose monitoring in type 2 diabetes, suggesting improved outcomes.
This analysis provides insight into the cost-effectiveness of rt-CGM versus SMBG from the perspective of payers in New Zealand, demonstrating reductions in the risks of complications in addition to reductions in their associated costs.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: